Date published: 2026-5-15

1-800-457-3801

SCBT Portrait Logo
Seach Input

KPRP Activators

KPRP activators encompass a diverse group of chemical compounds that indirectly stimulate the functional activity of KPRP through various intracellular signaling pathways. Forskolin, by triggering adenylyl cyclase, escalates cAMP levels, facilitating the activation of cAMP-dependent pathways that enhance KPRP's role. IBMX and Rolipram, through the inhibition of phosphodiesterases, prevent the degradation of cAMP, thereby sustaining the activation of PKA, which ultimately leads to an upsurge in KPRP activity. Similarly, 8-Br-cAMP and Dibutyryl cAMP, as synthetic analogs of cAMP, bypass upstream receptors and directly activate PKA, ensuring a boost in KPRP's functional activity. Isoproterenol, a beta-adrenergic agonist, and Anandamide, engaging cannabinoid receptors, both lead to an elevation of cAMP, further potentiating the activity of PKA and thus KPRP. These mechanisms highlight the intricate network of cAMP-dependent signaling in modulating KPRP activity.

Additional compounds like PMA and Ionomycin exert their effects through PKC and calcium-dependent pathways, respectively, thus indirectly contributing to the enhancement of KPRP activity. PMA, an activator of PKC, may potentiate KPRP activity through PKC-dependent signaling cascades, while Ionomycin and A23187, through their roles as calcium ionophores, increase intracellular calcium, which in turn might activate calcium-dependent kinases that favor KPRP activity. Epigallocatechin gallate, by inhibiting specific kinases, can reduce negative regulation, leading to an indirect increase in KPRP function.

SEE ALSO...

Items 11 to 11 of 11 total

Display:

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

(−)-Epigallocatechin Gallate

989-51-5sc-200802
sc-200802A
sc-200802B
sc-200802C
sc-200802D
sc-200802E
10 mg
50 mg
100 mg
500 mg
1 g
10 g
$43.00
$73.00
$126.00
$243.00
$530.00
$1259.00
11
(1)

EGCG inhibits certain kinases, possibly leading to an enhanced activity of KPRP through reduced negative regulation.